AU Patent

AU2014250762A1 — Highly active nucleoside derivative for the treatment of HCV

Assigned to Achillion Pharmaceuticals Inc · Expires 2015-10-29 · 11y expired

What this patent protects

A deuterated nucleoside analog of the formula and the pharmaceutically acceptable salts thereof are provided by this disclosure. The disclosure also includes pharmaceutical compositions comprising a compound or salt of the formula and a carrier. Compounds and salts of this formul…

USPTO Abstract

A deuterated nucleoside analog of the formula and the pharmaceutically acceptable salts thereof are provided by this disclosure. The disclosure also includes pharmaceutical compositions comprising a compound or salt of the formula and a carrier. Compounds and salts of this formula are useful for treating viral infections, including HCV infections. A method for treating a host afflicted with hepatitis C or other disorders is also presented that includes administering an effective treatment amount of a nucleoside or nucleotide that has deuterium with at least 50% enrichment at the 5'-position of the nucleoside or nucleotide.

Drugs covered by this patent

Patent Metadata

Patent number
AU2014250762A1
Jurisdiction
AU
Classification
—
Expires
2015-10-29
Drug substance claim
No
Drug product claim
No
Assignee
Achillion Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.